Date: 2012-10-09
Type of
information: Publication of results in a medical journal
phase: 1-2
Announcement: publication of results in the International Journal of Colorectal Disease
Company: Tigenix (Belgium)
Product: Cx601 (adipose derived allogeneic stem cell therapy)
Action
mechanism:
- cell therapy. Cx601 is a suspension of expanded allogeneic adult stem cell product derived from human adipose (fat) tissue (expanded Adipose derived Stem Cells or eASCs) that is delivered locally in the fistula through intra-lesional injection.
Disease: perianal fistulas in Crohn\'s disease patients
Therapeutic
area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Country:
Trial
details:
Latest
news:
- TiGenix has announced the publication in the International Journal of Colorectal Disease of the Phase 1-2 study of Cx601: Expanded allogeneic adipose-derived stems cells (eASCs) for the treatment of complex perianal fistula in Crohn\'s disease: results from a multicenter phase I/II clinical trial. The authors of the study state that the full analysis of efficacy data at week 24 showed 69.2% of the patients with a reduction in the number of draining fistulas, while 56.3% of the patients achieved complete closure of the treated fistula, and 30% of the cases presented complete closure of all existing fistula tracts. Cx601 is currently being investigated in the ADMIRE-CD Phase III study .
Is
general: Yes
